JP2018514199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018514199A5
JP2018514199A5 JP2017552966A JP2017552966A JP2018514199A5 JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5 JP 2017552966 A JP2017552966 A JP 2017552966A JP 2017552966 A JP2017552966 A JP 2017552966A JP 2018514199 A5 JP2018514199 A5 JP 2018514199A5
Authority
JP
Japan
Prior art keywords
replicable
transgene
oncolytic virus
adenovirus
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017552966A
Other languages
English (en)
Japanese (ja)
Other versions
JP6931229B2 (ja
JP2018514199A (ja
Filing date
Publication date
Priority claimed from GBGB1507419.8A external-priority patent/GB201507419D0/en
Priority claimed from GBGB1516936.0A external-priority patent/GB201516936D0/en
Priority claimed from GBGB1522013.0A external-priority patent/GB201522013D0/en
Priority claimed from PCT/EP2016/059609 external-priority patent/WO2016174200A1/en
Application filed filed Critical
Priority to JP2018041788A priority Critical patent/JP6928380B2/ja
Publication of JP2018514199A publication Critical patent/JP2018514199A/ja
Publication of JP2018514199A5 publication Critical patent/JP2018514199A5/ja
Priority to JP2021129196A priority patent/JP7162929B2/ja
Publication of JP6931229B2 publication Critical patent/JP6931229B2/ja
Application granted granted Critical
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017552966A 2015-04-30 2016-04-29 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス Active JP6931229B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018041788A JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1507419.8A GB201507419D0 (en) 2015-04-30 2015-04-30 Virus
GB1507419.8 2015-04-30
GB1516936.0 2015-09-24
GBGB1516936.0A GB201516936D0 (en) 2015-09-24 2015-09-24 Virus
GBGB1522013.0A GB201522013D0 (en) 2015-12-14 2015-12-14 Virus
GB1522013.0 2015-12-14
PCT/EP2016/059609 WO2016174200A1 (en) 2015-04-30 2016-04-29 Oncolytic adenovirus encoding a b7 protein

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2018041788A Division JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Division JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Publications (3)

Publication Number Publication Date
JP2018514199A JP2018514199A (ja) 2018-06-07
JP2018514199A5 true JP2018514199A5 (enExample) 2019-06-06
JP6931229B2 JP6931229B2 (ja) 2021-09-01

Family

ID=56008588

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017552966A Active JP6931229B2 (ja) 2015-04-30 2016-04-29 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2018041788A Active JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Active JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018041788A Active JP6928380B2 (ja) 2015-04-30 2018-03-08 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
JP2021129196A Active JP7162929B2 (ja) 2015-04-30 2021-08-05 Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス

Country Status (31)

Country Link
US (6) US11000559B2 (enExample)
EP (2) EP3288573B1 (enExample)
JP (3) JP6931229B2 (enExample)
KR (4) KR102854512B1 (enExample)
CN (2) CN107690479B (enExample)
AU (3) AU2016256582B2 (enExample)
BR (2) BR122018004815A2 (enExample)
CA (1) CA2984038C (enExample)
CL (2) CL2017002731A1 (enExample)
CO (1) CO2017010831A2 (enExample)
CY (1) CY1122833T1 (enExample)
DK (1) DK3288573T3 (enExample)
EA (1) EA037611B1 (enExample)
ES (1) ES2780366T3 (enExample)
HR (1) HRP20200439T1 (enExample)
HU (1) HUE048320T2 (enExample)
IL (3) IL284375B (enExample)
LT (1) LT3288573T (enExample)
MX (1) MX2017013684A (enExample)
MY (1) MY183703A (enExample)
PE (2) PE20181140A1 (enExample)
PH (1) PH12017501942A1 (enExample)
PL (1) PL3288573T3 (enExample)
PT (1) PT3288573T (enExample)
RS (1) RS60105B1 (enExample)
SA (2) SA520412637B1 (enExample)
SG (3) SG11201708604TA (enExample)
SI (1) SI3288573T1 (enExample)
SM (1) SMT202000222T1 (enExample)
WO (1) WO2016174200A1 (enExample)
ZA (1) ZA201801589B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112516179A (zh) 2013-06-14 2021-03-19 普赛奥克苏斯治疗公司 用于b型腺病毒的给药方案及制剂
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
SG11201708604TA (en) 2015-04-30 2017-11-29 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
EA201891022A1 (ru) * 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
HUE072880T2 (hu) * 2016-03-31 2025-12-28 The European Molecular Biology Laboratory Adenovírus szálfehérjékbõl származó módosított polipeptidek és a polipeptideket tartalmazó VLP-k
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
CA3035615A1 (en) * 2016-09-02 2018-03-08 Lentigen Technology, Inc. Compositions and methods for treating cancer with duocars
AU2017335673B2 (en) 2016-09-27 2024-11-14 Sator Therapeutics LLC Optimized oncolytic viruses and uses thereof
WO2018083257A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083258A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) * 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
AU2018215558B2 (en) * 2017-02-03 2023-05-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Oncolytic virus therapy
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
BR112019024656A2 (pt) * 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
KR102702230B1 (ko) * 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
JP7394628B2 (ja) * 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
US11573230B2 (en) * 2018-01-26 2023-02-07 Nantcell, Inc. Rapid verification of virus particle production for a personalized vaccine
GB201801614D0 (en) * 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
US12404312B2 (en) 2018-03-05 2025-09-02 Massachusetts Eye And Ear Infirmary Engineered VEGF variants for retinal neuroprotection, promotion of axon growth and axon regeneration
WO2019189643A1 (ja) * 2018-03-30 2019-10-03 国立大学法人東京大学 腫脹発生抑制型腫瘍溶解性ウイルス
EP3856216A4 (en) * 2018-09-10 2022-10-05 Genesail Biotech (Shanghai) Co. Ltd. MODIFIED ONCOLYTIC VIRUS, COMPOSITION AND USE THEREOF
TW202045544A (zh) 2019-02-22 2020-12-16 美商戊瑞治療有限公司 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白
AU2020232264B2 (en) * 2019-03-05 2026-02-19 Amgen Inc. Use of oncolytic viruses for the treatment of cancer
EP3725323A1 (en) * 2019-04-17 2020-10-21 Targovax Asa Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
EP3970754A4 (en) * 2019-05-14 2023-08-02 Oncolys BioPharma, Inc. METHOD OF ADMINISTRATION OF ONCOLYTIC VIRUS TO TUMOR TISSUE AND DEVICE FOR ADMINISTRATION
GB201909081D0 (en) 2019-06-25 2019-08-07 Psioxus Therapeutics Ltd Method
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
GB202102049D0 (en) * 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
EP4332218A4 (en) * 2021-06-03 2024-09-18 Shanghai Yunying Biopharmaceutical Technology Co., Ltd. ONCOLYTIC VIRUS VECTOR AND USE THEREOF
AU2022349649A1 (en) 2021-09-23 2024-04-04 Sagittarius Bio, Inc. Adenoviruses and methods for using adenoviruses
EP4499846A1 (en) * 2022-03-25 2025-02-05 Universität Zürich Adenoviral mediated targeting of activated immune cells
WO2024243578A1 (en) 2023-05-25 2024-11-28 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CN1115414C (zh) 1993-07-13 2003-07-23 罗纳-布朗克罗莱尔股份有限公司 用于基因治疗的病毒载体
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5830686A (en) 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5877011A (en) 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
CN1242051A (zh) 1996-12-31 2000-01-19 昂尼克斯药物公司 用于肿瘤治疗和预防的致细胞病变病毒
EP1036183B1 (en) 1997-02-20 2007-10-03 The Johns Hopkins University School Of Medicine Mutations in atp-dependent transposition proteins that reduce target-site specificity
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US6291214B1 (en) 1998-05-11 2001-09-18 Glaxo Wellcome Inc. System for generating recombinant viruses
US20020019051A1 (en) 1998-05-27 2002-02-14 Monika Lusky Chimeric adenoviral vectors
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
CN1110553C (zh) 1998-07-15 2003-06-04 杭州赛狮生物技术开发有限公司 基因工程腺病毒及其用途
US6455314B1 (en) 1998-09-11 2002-09-24 Genvec, Inc. Alternatively targeted adenovirus
JP4409097B2 (ja) 1998-12-09 2010-02-03 アメリカ合衆国 複数の共刺激分子を発現する組換えベクターおよびその利用
ES2372823T3 (es) 1999-05-17 2012-01-26 Crucell Holland B.V. Adenovirus recombinante del serotipo ad11.
AU5464000A (en) 1999-06-01 2000-12-18 University Of Washington Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
US7396679B2 (en) 1999-11-15 2008-07-08 Onyx Pharmaceuticals, Inc. Oncolytic adenovirus
ATE312189T1 (de) * 2000-01-21 2005-12-15 Biovex Ltd Virusstämme für die onkolytische behandlung von krebs
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
AU2001265154A1 (en) 2000-05-31 2001-12-11 Genvec, Inc. Method and composition for targeting an adenoviral vector
US7459153B2 (en) 2001-01-04 2008-12-02 Wadell Goeran Viral vectors for gene therapy
US20050175589A1 (en) 2001-07-13 2005-08-11 Btg International Limited Anti-neoplastic viral agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1470233A1 (en) * 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
CN1705740B (zh) * 2002-10-15 2013-07-24 佩尔·松内·霍尔姆 具有反向基因表达的腺病毒及其应用
US20040167088A1 (en) 2003-02-25 2004-08-26 Genvec, Inc. Method of using adenoviral vectors with increased persistence in vivo
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
US20050136035A1 (en) 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
CA2527369A1 (en) 2003-07-18 2005-02-03 Onyx Pharmaceuticals, Inc. Subgroup b adenoviral vectors for treating disease
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20080292592A1 (en) 2004-04-30 2008-11-27 Sunil Chada Oncolytic Adenovirus Armed with Therapeutic Genes
WO2005118825A2 (en) 2004-05-26 2005-12-15 Schering Aktiengesellschaft Chimeric adenoviruses for use in cancer treatment
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CN101068933A (zh) * 2004-08-25 2007-11-07 细胞基因系统有限公司 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
DE102005055128B4 (de) 2005-11-15 2015-04-02 Universität Rostock Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor
ES2304281B1 (es) 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
EP2094284A2 (en) 2006-12-22 2009-09-02 Bayer Schering Pharma AG Generation of oncolytic adenoviruses and uses thereof
TW200951143A (en) 2008-05-27 2009-12-16 Oncolytics Biotech Inc Modulating interstitial pressure and oncolytic viral delivery and distribution
CN101381742A (zh) 2008-10-23 2009-03-11 浙江理工大学 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
EP2486137B1 (en) * 2009-10-05 2018-05-30 Ya-Fang Mei Replication-competent ad11p based viral vectors
CN103237889B (zh) 2010-08-16 2017-04-05 萨克生物研究学院 腺病毒组装方法
BR112013006699A2 (pt) 2010-09-24 2016-06-14 Oncos Therapeutics Oy vetor adenoviral oncolítico que codifica anticorpos anti-ctl4-4 monoclonais, célula e composição farmacêutica compreendendo o mesmo, método de produção de anticorpo monoclonal humano específico para ctla-4 em uma célula e uso do referido vetor adenoviral
EP2619224A1 (en) * 2010-09-24 2013-07-31 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
WO2013074507A2 (en) 2011-11-14 2013-05-23 Regenerative Sciences, Llc Suspended particle delivery systems and methods
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
CN105407902A (zh) 2013-03-05 2016-03-16 贝勒医学院 溶瘤病毒
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
KR20160137946A (ko) 2013-11-22 2016-12-02 디엔에이트릭스, 인코포레이티드 면역 세포 자극성 수용체 작용제(들)를 발현하는 아데노바이러스
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
GB201510197D0 (en) * 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
GB201503500D0 (en) 2015-03-02 2015-04-15 Ucl Business Plc Cell
AU2016232009B2 (en) 2015-03-17 2021-07-15 Tilt Biotherapeutics Oy Oncolytic adenoviruses coding for bi-specific antibodies and methods and uses related thereto
SG11201708604TA (en) 2015-04-30 2017-11-29 Psioxus Therapeutics Ltd Oncolytic adenovirus encoding a b7 protein
EA201891022A1 (ru) 2015-12-17 2019-01-31 Псайоксус Терапьютикс Лимитед Вирус, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
SG11201808058PA (en) 2016-03-18 2018-10-30 Nantcell Inc Multimodal vector for dendritic cell infection
MY197324A (en) 2016-08-29 2023-06-13 Akamis Bio Ltd Adenovirus armed with bispecific t cell activator
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018083258A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding at least three transgenes
WO2018083259A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
WO2018083257A1 (en) 2016-11-03 2018-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding transgenes
JP7394628B2 (ja) * 2017-06-01 2023-12-08 アカミス バイオ リミテッド 腫瘍溶解性ウイルスおよび方法
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation

Similar Documents

Publication Publication Date Title
Sharma et al. Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Conlon et al. Cytokines in the treatment of cancer
RU2703438C2 (ru) Расширенная адоптивная клеточная терапия
US20220162279A1 (en) Combination immunotherapy
JP2018139586A5 (enExample)
Homey et al. Chemokines: agents for the immunotherapy of cancer?
TWI850282B (zh) 用於治療癌症之質體建構體和使用方法
JP2024096876A (ja) 一本鎖および多鎖キメラポリペプチドならびにその使用方法
Sandau et al. IL-15 regulates both quantitative and qualitative features of the memory CD8 T cell pool
HRP20200439T1 (hr) Onkolitički adenovirus koji kodira protein b7
JP2017006118A (ja) 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
AU2018277294A1 (en) Oncolytic virus and method
US20220125951A1 (en) Microenvironment sensors to regulate engineered gene expression
JP2026000910A (ja) 免疫回避腫瘍の処置
Cervera-Carrascon et al. Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.
WO2021259206A1 (zh) 针对sars-cov-2病毒的dna疫苗及其用途
Rossari et al. Gene-based delivery of immune-activating cytokines for cancer treatment
Zhang et al. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma
Lo et al. Differential antitumor effect of interleukin‐12 family cytokines on orthotopic hepatocellular carcinoma
Pistoia et al. Cytokines in neuroblastoma: from pathogenesis to treatment
Gao et al. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer
Stewart et al. Chemokine–chemokine receptors in cancer immunotherapy
Mirbahari et al. Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade
Paul et al. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer
CA3183322A1 (en) Methods of determining responsiveness to cancer immunotherapy